Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05938270
Other study ID # D9721C00002
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 21, 2023
Est. completion date February 25, 2025

Study information

Verified date May 2024
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN)


Description:

An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) alone, Darolutamide alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN)


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date February 25, 2025
Est. primary completion date February 25, 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - male participants >/= 18 years old - participants deemed suitable for radical prostatectomy - participants with localised prostate cancer with unfavourable intermediate/high/very high risk eligible for prostatectomy - adequate organ and marrow function as per protocol - capable of giving signed informed consent - provision of signed and dated written Optional Genetic Research Information - Available FFPE diagnostic tumour biopsy samples - Participants must use a condom (with spermicide) from screening to 6 months after screening and refrain from fathering a child or donating sperm Exclusion Criteria: - As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including, active bleeding diatheses, or active infection including HepB, hepatitis C and HIV. Screening for chronic conditions is not required. 1. Active HBV is defined by a known positive HBsAg result. Participants with a past or resolved HBV infection (defined as the presence of HepB antibody and absence of HBsAg) are eligible. 2. Participants positive for HCV antibody are eligible only if PCR is negative for HCV RNA. - Participants with any known predisposition to bleeding (eg, active peptic ulceration, recent [within 6 months] haemorrhagic stroke, proliferative diabetic retinopathy). - Participants with history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). Specific screening for MDS/AML not required. - Prior malignancy within 3 years of screening whose natural history, in the Investigator's opinion, has the potential to interfere with safety and efficacy assessments of the investigational regimen. - Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of TdP. - Any of the following cardiac criteria: 1. Mean resting corrected QT interval (QTcF) > 450 milliseconds or QTcF < 340 milliseconds obtained from triplicate ECGs and averaged, recorded within 5 minutes. 2. Any factors that increase the risk of QT prolongation, shortening or risk of arrhythmic events such as hypokalaemia, congenital long or short QT syndrome, family history of long QT syndrome, familial short QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong or shorten the QT interval. 3. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, second or third degree atrioventricular block and clinically significant sinus node dysfunction not treated with pacemaker. - Other CVS diseases as defined by any of the following: 1. Symptomatic heart failure (as defined by NYHA class = 2). 2. uncontrolled hypertension. 3. hypertensive heart disease with significant left ventricular hypertrophy. 4. History of acute coronary syndrome/acute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention or coronary artery bypass grafting within 6 months prior to screening. 5. cardiomyopathy of any aetiology. 6. presence of clinically significant valvular heart disease. 7. history of atrial or ventricular arrhythmia requiring acute treatment; participants with atrial fibrillation and optimally controlled ventricular rate (heart rate < 100 bpm) are permitted. 8. transient ischaemic attack, or stroke within 6 months prior to screening. 9. participants with symptomatic hypotension at screening. - Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of Saruparib (AZD5305). - History of prior malignancy, treated with chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, or other anticancer agent within 3 years of screening. Previously localised surgically treated malignancy is acceptable, if no evidence of recurrence. - Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s). - Prior treatment with any systemic or localised anti-cancer treatment for the localised prostate cancer. - During the 4 weeks prior to the first dose, receiving immune modulatory agents including but not limited to, continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent. - Concomitant use of medications or herbal supplements known to be: 1. Strong CYP3A4 inducers/inhibitors (applies for Saruparib (AZD5305) and Saruparib (AZD5305) + darolutamide arms) 2. Strong or moderate CYP3A4 and P-glycoprotein inducers (applies to darolutamide arm and Saruparib (AZD5305) + darolutamide arm) This is including, but not limited to, the prohibited medications listed in CSP Appendix G, or inability to stop the use thereof, at least 21 days or at least 5 half-lives (whichever is longer) before the first dose of study treatment until 30 days after the last dose of study treatment. - Treatment with any investigational agents or study interventions from a previous clinical study within 5 half-lives or 3 weeks (whichever is longer) of the first dose of study treatment. - Participants with contraindication to darolutamide for treatment arms - Unable to comply with the visits and assessments. - In the opinion of the Investigators should not be included in this study. No treatment arm only: if any participant meets exclusion 4, 9 or 11, they are not to be included in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Saruparib (AZD5305)
Saruparib (AZD5305) given orally once daily
Darolutamide
Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
Other:
No Treatment
No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice

Locations

Country Name City State
Australia Research Site Melbourne
Australia Research Site South Brisbane
Canada Research Site Québec Quebec
Canada Research Site Toronto Ontario
Canada Research Site Vancouver British Columbia
Netherlands Research Site Amsterdam
Netherlands Research Site Nijmegen
Spain Research Site Barcelona
Spain Research Site Barcelona
Spain Research Site Madrid
Spain Research Site Valencia
United Kingdom Research Site Cambridge
United Kingdom Research Site Manchester
United Kingdom Research Site Newcastle upon Tyne
United States Research Site Detroit Michigan
United States Research Site Providence Rhode Island
United States Research Site Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fold change in % ?H2AX positive cells from baseline value in tumour samples To assess the effects of study treatment on ?H2AX change in participants with localised prostate cancer Tumour biopsy taken at diagnosis within approx 2 months of Day 1 planned start of study treatment; post treatment tumour biopsy taken following 21 days (+ up to 7 days) of study treatment
Secondary Severity of Treatment-Emergent AEs/SAEs per CTCAE v5.0 To assess the safety and tolerability of study treatment in participants with localised prostate cancer Day 1 to 28 days post-surgery
Secondary Incidence of Treatment-Emergent AEs/SAEs per CTCAE v5.0 To assess the safety and tolerability of study treatment in participants with localised prostate cancer Day 1 to 28 days post-surgery
Secondary Number of patients with abnormal laboratory values To assess the safety and tolerability of study treatment in participants with localised prostate cancer Day 1 to 28 days post-surgery
Secondary Change from baseline in blood pressure reported as clinically significant To assess the safety of study treatment in participants with localised prostate cancer Day 1 to 28 days post-surgery
Secondary Change from baseline in heart rate reported as clinically significant To assess the safety of study treatment in participants with localised prostate cancer Day 1 to 28 days post-surgery
Secondary Change from baseline in QTc value To assess the safety of study treatment in participants with localised prostate cancer Day 1 to 28 days post-surgery
Secondary Number of participants undergoing planned surgery To assess the impact of study treatment on surgical feasibility in participants with localised prostate cancer Measured based on Day 1 to Day 21 of treatment
Secondary Reasons of participants requiring treatment-related and non-treatment related delays of surgery and delays > 7 days from scheduled day To assess the impact of study treatment on surgical feasibility in participants with localised prostate cancer Measured based on Day 1 to Day 21 of treatment
Secondary Number of participants requiring treatment-related and non-treatment related delays of surgery and delays > 7 days from scheduled day To assess the impact of study treatment on surgical feasibility in participants with localised prostate cancer Measured based on Day 1 to Day 21 of treatment
Secondary Change in Ki-67 % positive cells from baseline in tumour samples To assess the effects of study treatment on Ki-67 change in participants with localised prostate cancer Measured based on Day 1 to Day 21 of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A